With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks
PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.
You may also be interested in...
Biogen's Singhal On Stepping Into R&D Leadership Shoes Amid Aduhelm Controversy
Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.
Aduhelm Adverse Event Reports Come In, Another Potential Hurdle To Uptake
One patient treated with Aduhelm died who was diagnosed with cerebral edema thought to be ARIA-E, a known risk, Biogen confirmed.
Lilly Is Revved Up About Alzheimer's Opportunity
The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody.